文献速递新发突发、热带与寄生虫病医院感染防控

Ad26.ZEBOV与MVA-BN-Filo两剂埃博拉疫苗方案在塞拉利昂成人中的安全性和长期免疫原性

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
PubMed 文献 · Lancet Infect Dis · 2021-09-13

该试验在塞拉利昂采用开放标签非随机1期和随机双盲对照2期设计,评估Ad26.ZEBOV初免、MVA-BN-Filo加强的两剂异源埃博拉疫苗方案。结果显示方案耐受良好,无疫苗相关严重不良事件,第二剂后21天98%的受试者产生体液免疫应答。

要点

  • 两剂异源埃博拉疫苗方案在成人中耐受良好,未发现疫苗相关严重不良事件。
  • 第二剂后21天,1期和2期分别有98%的受试者产生埃博拉病毒糖蛋白特异性结合抗体。
  • 2期随机对照中,疫苗组与MenACWY对照组的不良事件谱相似,多为轻中度。

核心结论

  • Ad26.ZEBOV与MVA-BN-Filo两剂方案耐受良好且具有免疫原性,并诱导持续体液免疫应答,支持用于成人埃博拉病毒病预防。

研究设计与样本

  • 研究包含开放标签非随机1期和随机双盲对照2期,在塞拉利昂Kambia区三家诊所开展。
  • 共入组443名健康成人(1期43人,2期400人),2期按3:1随机分配至疫苗组或MenACWY对照组。
  • 1期受试者在首剂后2年接受Ad26.ZEBOV加强接种,评估加强针安全性和耐受性。

主要发现

  • 1期首剂Ad26.ZEBOV后局部征集性不良事件报告12/43(28%),第二剂MVA-BN-Filo后6/43(14%)。
  • 2期首剂Ad26.ZEBOV后局部征集性不良事件51/298(17%),第二剂MVA-BN-Filo后58/246(24%),MenACWY后17/102(17%),安慰剂后8/86(9%)。
  • 2期首剂Ad26.ZEBOV后全身征集性不良事件161/298(54%),第二剂MVA-BN-Filo后107/246(43%),MenACWY后51/102(50%),安慰剂后39/86(45%)。
  • 第二剂后21天,1期41/42(98%)受试者产生结合抗体(GMC 4784 EU/mL,95%CI 3736-6125),2期176/179(98%)产生结合抗体(GMC 3810 EU/mL,95%CI 3312-4383)。

关键数值与推荐

  • 1期Ad26.ZEBOV剂量为5×10^10病毒颗粒,MVA-BN-Filo剂量为1×10^8感染单位,分别于第1天和第57天肌内注射。
  • 2期疫苗组接受Ad26.ZEBOV后MVA-BN-Filo,对照组接受单剂MenACWY后安慰剂。
  • 安全性评估包括每次接种后7天内征集性局部和全身不良事件、28天内非征集性不良事件及至末次访视的严重不良事件。

临床怎么用

  • 该两剂异源方案可用于成人埃博拉病毒病预防,耐受性良好且免疫原性高。
  • 接种后常见轻中度局部和全身反应,未观察到疫苗相关严重不良事件。
  • 首剂后2年加强接种的安全性与首剂后相似,支持加强策略。

局限性

  • 1期为非随机开放标签设计,样本量较小(43人)。
  • 免疫原性分析基于符合方案集,排除了存在重大方案偏离的受试者。
  • 长期免疫原性数据仅限于首剂后2年加强接种时的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Ebola epidemics in west Africa and the Democratic Republic of the Congo highlight an urgent need for safe and effective vaccines to prevent Ebola virus disease. We aimed to assess the safety and long-term immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based vaccine encoding the Ebola virus glycoprotein (Ad26.ZEBOV) and the modified vaccinia Ankara vector-based vaccine, encoding glycoproteins from Ebola virus, Sudan virus, and Marburg virus, and the nucleoprotein from the Tai Forest virus (MVA-BN-Filo), in Sierra Leone, a country previously affected by Ebola. METHODS: The trial comprised two stages: an open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2. The study was done at three clinics in Kambia district, Sierra Leone. In stage 1, healthy adults (aged ≥18 years) residing in or near Kambia district, received an intramuscular injection of Ad26.ZEBOV (5 × 1010 viral particles) on day 1 (first dose) followed by an intramuscular injection of MVA-BN-Filo (1 × 108 infectious units) on day 57 (second dose). An Ad26.ZEBOV booster vaccination was offered at 2 years after the first dose to stage 1 participants. The eligibility criteria for adult participants in stage 2 were consistent with stage 1 eligibility criteria. Stage 2 participants were randomly assigned (3:1), by computer-generated block randomisation (block size of eight) via an interactive web-response system, to receive either the Ebola vaccine regimen (Ad26.ZEBOV followed by MVA-BN-Filo) or an intramuscular injection of a single dose of meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (MenACWY; first dose) followed by placebo on day 57 (second dose; control group). Study team personnel, except those with primary responsibility for study vaccine preparation, and participants were masked to study vaccine allocation. The primary outcome was the safety of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen, which was assessed in all participants who had received at least one dose of study vaccine. Safety was assessed as solicited local and systemic adverse events occurring in the first 7 days after each vaccination, unsolicited adverse events occurring in the first 28 days after each vaccination, and serious adverse events or immediate reportable events occurring up to each participant's last study visit. Secondary outcomes were to assess Ebola virus glycoprotein-specific binding antibody responses at 21 days after the second vaccine in a per-protocol set of participants (ie, those who had received both vaccinations within the protocol-defined time window, had at least one evaluable post-vaccination sample, and had no major protocol deviations that could have influenced the immune response) and to assess the safety and tolerability of the Ad26.ZEBOV booster vaccination in stage 1 participants who had received the booster dose. This study is registered at ClinicalTrials.gov, NCT02509494. FINDINGS: Between Sept 30, 2015, and Oct 19, 2016, 443 participants (43 in stage 1 and 400 in stage 2) were enrolled; 341 participants assigned to receive the Ad26.ZEBOV and MVA-BN-Filo regimen and 102 participants assigned to receive the MenACWY and placebo regimen received at least one dose of study vaccine. Both regimens were well tolerated with no safety concerns. In stage 1, solicited local adverse events (mostly mild or moderate injection-site pain) were reported in 12 (28%) of 43 participants after Ad26.ZEBOV vaccination and in six (14%) participants after MVA-BN-Filo vaccination. In stage 2, solicited local adverse events were reported in 51 (17%) of 298 participants after Ad26.ZEBOV vaccination, in 58 (24%) of 246 after MVA-BN-Filo vaccination, in 17 (17%) of 102 after MenACWY vaccination, and in eight (9%) of 86 after placebo injection. In stage 1, solicited systemic adverse events were reported in 18 (42%) of 43 participants after Ad26.ZEBOV vaccination and in 17 (40%) after MVA-BN-Filo vaccination. In stage 2, solicited systemic adverse events were reported in 161 (54%) of 298 participants after Ad26.ZEBOV vaccination, in 107 (43%) of 246 after MVA-BN-Filo vaccination, in 51 (50%) of 102 after MenACWY vaccination, and in 39 (45%) of 86 after placebo injection. Solicited systemic adverse events in both stage 1 and 2 participants included mostly mild or moderate headache, myalgia, fatigue, and arthralgia. The most frequent unsolicited adverse event after the first dose was headache in stage 1 and malaria in stage 2. Malaria was the most frequent unsolicited adverse event after the second dose in both stage 1 and 2. No serious adverse event was considered related to the study vaccine, and no immediate reportable events were observed. In stage 1, the safety profile after the booster vaccination was not notably different to that observed after the first dose. Vaccine-induced humoral immune responses were observed in 41 (98%) of 42 stage 1 participants (geometric mean binding antibody concentration 4784 ELISA units [EU]/mL [95% CI 3736-6125]) and in 176 (98%) of 179 stage 2 participants (3810 EU/mL [3312-4383]) at 21 days after the second vaccination. INTERPRETATION: The Ad26.ZEBOV and MVA-BN-Filo vaccine regimen was well tolerated and immunogenic, with persistent humoral immune responses. These data support the use of this vaccine regimen for Ebola virus disease prophylaxis in adults. FUNDING: Innovative Medicines Initiative 2 Joint Undertaking and Janssen Vaccines & Prevention BV.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ishola D, Manno D, Afolabi MO, et al. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infect Dis. 2021. PMID: 34529963. doi:10.1016/S1473-3099(21)00125-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。